Price $82.05 |
Market Cap
135B
|
Sector Health Care |
Div. Growth
7.90%
|
|
P/E
51.2
|
P/B
4.34
|
P/S
4.37
|
Dividend %
1.70%
|
|
P/CF
-
|
P/FCF
56.1
|
Op. Cash Flow
5.9M
|
FCF
1.3
|
|
Op. Margin
11.80%
|
Net Margin
8.50%
|
ROE
8.50%
|
ROI
6.10%
|
|
ROA
3.80%
|
EPS Growth
445.30%
|
Current Ratio
1.6
|
Debt/Equity
63.40%
|
| Company | Price | P/E | Div. Yield | Market Cap ($Mil) | Rating |
|---|---|---|---|---|---|
| R1 RCM Inc (RCM) | $11.80 | - | - | 1.32B | Strong Buy |
| Harvard Bioscience, Inc. (HBIO) | $2.10 | - | - | 87.4M | Strong Buy |
| Invo Bioscience Inc (IVOB) | $0.39 | - | - | 56.6M | Strong Buy |
| Fulgent Genetics Inc (FLGT) | $5.78 | - | - | 106.5M | Strong Buy |
| Esperion Therapeutics Inc (ESPR) | $51.31 | - | - | 1.31B | Strong Buy |
Please note that all recommendations are based on our model's results and do not represent our personal opinion. The stock Rating process is purely mechanical.
All analysis relies on publicly available financial information. Learn More
